303360.KQ Protia Inc.

Healthcare Diagnostics & Research KOSDAQ
3,660 KRW
Close of Oct 30, 2026
2,453 4,593
Market cap
KRW 70.7B
P/E
12.7x
P/B
2.13x
ROE
15.2%
Dividend yield
-
Fundamental score
1.6/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 303360.KQ undervalued?

Graham number
Price3,660
Graham value3,340
Premium9.6%

303360.KQ trades 9.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Protia Inc. fundamental analysis

8 of 22 checks passed

ROE 1/2

Moderate return on equity (15.2%), between 10% and 20%.

ROA 1/1

Return on assets (14.4%) is above the industry median (-10.2%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (83.1%) is above the industry median (46.9%).

Revenue Growth 2/2

Revenue grew 25.5% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 608.2x against interest expense, well covered.

PE vs Market 0/1

PE (12.7x) is above the market median (11.3x).

PE vs Industry 0/1

PE (12.7x) is above the industry median (11.3x).

PBV 0/1

Price to book (2.1x) is above the industry median (1.6x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 27.0, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Protia Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Protia Inc.

Protia Inc. manufactures and sells in vitro diagnostic medical devices in South Korea. It offers allergy, animal diagnosis, autoimmune, antibiotic susceptibility, POCT, cancer, and related instrument products, as well as protein analysis, LC-MS/MS, characterization analysis, and custom protein services. The company was formerly known as ProteomeTech Inc. and changed its name to Protia Inc. in November 2023. Protia Inc. was founded in 2000 and is headquartered in Seoul, South…

Full company profile